CJC-1295 / Ipamorelin
GHRH analog + GHRP blend
A gentler growth hormone pulse.
Half-life
~ 30 min (CJC-1295 no DAC and ipamorelin)
Mol. weight
~3,368 g/mol (mod GRF 1-29) + 712 g/mol (ipamorelin)
Sequence
mod GRF(1-29) + Aib-His-D-2-Nal-D-Phe-Lys-NH2 (blend)
Discussions
0 threads
Overview
A combination of a growth hormone-releasing hormone (GHRH) analog (CJC-1295 without DAC) and a growth hormone-releasing peptide (Ipamorelin). The pairing is researched because the two act on different parts of the GH-release cascade — GHRH signaling at the pituitary somatotrophs and ghrelin-receptor (GHS-R1a) stimulation — producing a synergistic, pulsatile release of growth hormone that mimics the body's natural rhythm rather than the sustained elevation seen with exogenous GH.
Mechanism of action
CJC-1295 (mod GRF 1-29) binds GHRH receptors on pituitary somatotrophs to amplify the amplitude of natural GH pulses, with a half-life of roughly 30 minutes that preserves the pulsatile pattern. Ipamorelin agonizes the ghrelin receptor (GHS-R1a), adding a second stimulus to the same cells. Because the two peptides act through distinct receptors that converge on growth-hormone release, they produce a larger combined GH pulse than either alone, while the short half-life of both components helps avoid the continuous GH elevation that suppresses endogenous production.
Researched benefits
- Supports natural, pulsatile GH release
- May improve sleep quality and recovery
- Research suggests body-composition support
- Lower appetite impact than GHRP-6 thanks to ipamorelin's selectivity
Considerations
- Effects are gradual, not acute
- Quality sourcing is critical
- Use under professional guidance only
Key Academic Literature & Studies
Search more in PubMedPeer-reviewed citations and clinical trials evaluating CJC-1295 / Ipamorelin in scientific literature.
Query PubMed for recent peer-reviewed preclinical and clinical publications on CJC-1295 / Ipamorelin:
View CJC-1295 / Ipamorelin index on PubMed (NCBI)